The NHS-Galleri trial is looking into the use of a new blood test to see if it can help the NHS to detect cancer early when used alongside existing cancer screening.

140,000 people have volunteered to take part in the trial across England. Since August 2023 the trial has been inviting participants to return for their last of three trial appointments. If you receive an invitation letter, please follow the instructions to book an appointment online or via the dedicated phone line. The trial is not accepting new participants at this time.

If you are a participant and your address and/or contact details have changed since you joined the trial, please go to nhs.galleri.org/check to update your details.

It is important for the trial that as many people as possible attend their appointments. This will help research to understand how the blood test could be offered to people in the future.

Please remember that you should continue to attend any cancer screening visits you are invited to and visit your GP if you experience any symptoms which are new or unusual for you.

The study is being carried out in partnership with NHS England and GRAIL Bio UK Ltd, and is being run by The Cancer Research UK & King’s College London Cancer Prevention Trials Unit, a team of cancer researchers and trial managers at King’s College London.

GRAIL LLC is a company in the United States that developed the test. They have also set up a branch in the UK, GRAIL Bio UK Ltd (GRAIL), who are the main funder and organiser of this trial.

For more information, visit NHS-Galleri Trial | Detecting cancer early.